Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal extends ...
Danish drugmaker Novo Nordisk (NVO) (OTCPK:NONOF) and AI-focused biotech Valo Health announced Wednesday an agreement to ...
31mon MSN
Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback